Compare Neurocrine Biosciences Inc (NBIX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Royal Bank of Canada — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Royal Bank of Canada trades at $210.37 (market cap $289.51B). The key difference: Royal Bank of Canada is far larger — about 16.6× Neurocrine Biosciences Inc's market cap, and Royal Bank of Canada pays a 2.42% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RY | |
|---|---|---|
Market Cap | $17.40B | $289.51B |
Sector | Health | Financials |
52-Week High | $180.55 | $217.87 |
52-Week Low | $123.10 | $128.46 |
Enterprise Value | $16.49B | — |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
